Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
With demonstrated clinical development and commercialization expertise, VIVUS is d...
With demonstrated clinical development and comm...
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using ...
Constellation Pharmaceuticals is a clinical-sta...
Patient Access Solutions Inc provides administrative, management, and facility ser...
Patient Access Solutions Inc provides administr...
Altimmune is a clinical-stage immunotherapeutics company focused on the developmen...
Altimmune is a clinical-stage immunotherapeutic...
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...
Join the National Investor Network and get the latest information with your interests in mind.